Roth Capital Issues Pessimistic Outlook for Clene Earnings

Clene Inc. (NASDAQ:CLNN) – Roth Capital lowered their Q1 2025 earnings estimates for shares of Clene in a note issued to investors on Monday, March 24th. Roth Capital analyst J. Aschoff now anticipates that the company will post earnings per share of ($1.09) for the quarter, down from their previous estimate of ($0.86). The consensus estimate for Clene’s current full-year earnings is ($5.19) per share. Roth Capital also issued estimates for Clene’s Q2 2025 earnings at ($0.92) EPS, Q3 2025 earnings at ($0.92) EPS, Q4 2025 earnings at ($0.80) EPS, FY2025 earnings at ($3.68) EPS and FY2026 earnings at ($2.85) EPS.

A number of other analysts have also commented on the stock. HC Wainwright reissued a “buy” rating and issued a $31.00 price objective on shares of Clene in a research report on Monday. D. Boral Capital reaffirmed a “buy” rating and issued a $23.00 target price on shares of Clene in a research report on Monday. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $55.25.

Clene Price Performance

CLNN opened at $3.54 on Thursday. The company has a market capitalization of $29.47 million, a price-to-earnings ratio of -0.67 and a beta of 0.27. The business’s 50-day moving average price is $4.49 and its two-hundred day moving average price is $4.88. Clene has a 1 year low of $3.37 and a 1 year high of $9.20.

Clene (NASDAQ:CLNN) last issued its quarterly earnings data on Monday, March 24th. The company reported ($1.67) EPS for the quarter, missing analysts’ consensus estimates of ($1.21) by ($0.46). The company had revenue of $0.09 million for the quarter, compared to analyst estimates of $0.13 million. Clene had a negative return on equity of 1,106.30% and a negative net margin of 8,556.77%.

Hedge Funds Weigh In On Clene

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Fullcircle Wealth LLC acquired a new stake in shares of Clene in the fourth quarter valued at approximately $69,000. Renaissance Technologies LLC bought a new stake in Clene in the 4th quarter valued at $96,000. Geode Capital Management LLC lifted its holdings in Clene by 52.9% during the 4th quarter. Geode Capital Management LLC now owns 65,112 shares of the company’s stock valued at $346,000 after purchasing an additional 22,539 shares during the last quarter. SBI Securities Co. Ltd. bought a new position in Clene during the fourth quarter worth $69,000. Finally, Parsons Capital Management Inc. RI acquired a new position in shares of Clene in the fourth quarter valued at $194,000. Institutional investors own 23.28% of the company’s stock.

About Clene

Clene Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.